Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France
Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France
The first half 2026 reported revenue is the first without the negative impact of early access rebates
Reported revenue does not include royalties to be received from commercial partners on Sibnayal® sales
In the French market alone, Sibnayal® sales grew by 41% in volume
Reimbursement of Likozam® has high impact on its sales growth
Advicenne Granted Reimbursement for Likozam® in France and Sees Thereby Its Debt Reduced by Nearly €6 Million
Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain
Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom
Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million
Medincell Reports FY 2025-26 Annual Results
ABIONYX Pharma Provides an Update on Its Operations and Cash Position for the First Quarter of 2026
